The PROMAGEN Study: Viral pandemic link?

Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?

SUMMARY

An exploratory, block-randomised, parallel, double-blind, single-centre, placebo-controlled superiority study with 220 overweight and obese adults with BMI 25-34.9. The probiotic group (110) took 50 billion Lab4P probiotics every day for six months and the placebo group (110) took an identical looking placebo.
Supplementation with Lab4P probiotics significantly reduced the incidence of viral specific upper respiratory tract infection symptoms particularly in older or obese adults
Gut microbiota diversity remained stable in Lab4P supplemented older adults who developed upper respiratory tract infection symptoms.

Aim

This randomised, double-blind, placebo controlled study aimed to assess the effect of 6-months supplementation with the Lab4P probiotic on body weight, plasma cholesterol and well-being in healthy overweight and obese individuals. In addition, the further analyses was carried to investigate the impact of the Lab4P probiotic on the occurrence of the specific upper respiratory tract infection (URTI) symptoms and their relationship with age, BMI and gut microbiota diversity.

Method

Results

Overall URTI symptoms

  • Significant reduction in the incidence of URTI symptoms (cough, sore throat, headache, muscle pain and wheeze) in Group 2 compared to Group 1
  • (P< 0.0001).
  • The impact of Lab4 probiotic supplementation on the incidence of URTI symptoms was greater in participants 45 years and older or with BMI ³30 (Fig 1).
  • Season differences in the URTI symptoms occurrence

  • In both groups, the significantly fewer URTI symptoms were observed in the summer/early autumn months (July – September) compared to the late autumn/winter months (October-December).
  • Lab4P probiotic supplementation (Group 2) resulted in the lower incidence of URTI symptoms in both seasons compared to Group 1 (Fig 2).
  • Gut microbiota and URTI symptoms associations

  • In Group 1, the participants aged 45 and over showed a significant reduction in the diversity of gut microbiota with the increased number of days with URTI symptoms (P<05).
  • In contrary, the supplementation with Lab4P probiotics has minimised the changes in the composition of gut microbiota in the participants 45 years old and over with URTI symptoms (Group 2).
  • Conclusion

    Supplementation of overweight and obese adults with the Lab4P probiotic for 6 months resulted in a significant reduction in the incidence of specific URTI symptoms with greatest benefit in individuals 45 years and over and/or with BMI over 30. The Lab4P probiotics demonstrated a protective role in preventing changes in gut microbiota composition in the older participants who developed URTI symptoms.

    Study links

    2020

    The PROMAGEN Study: URTI Symptoms

    A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

    2020

    The PROMAGEN Study: Quality of Life

    A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

    2020

    The PROMAGEN Study: Weight loss and Cholesterol

    A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

    2021

    The PROBE Study

    Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults

    Scroll to Top